JP2023182689A5 - - Google Patents

Download PDF

Info

Publication number
JP2023182689A5
JP2023182689A5 JP2023169033A JP2023169033A JP2023182689A5 JP 2023182689 A5 JP2023182689 A5 JP 2023182689A5 JP 2023169033 A JP2023169033 A JP 2023169033A JP 2023169033 A JP2023169033 A JP 2023169033A JP 2023182689 A5 JP2023182689 A5 JP 2023182689A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid number
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023169033A
Other languages
English (en)
Japanese (ja)
Other versions
JP7822576B2 (ja
JP2023182689A (ja
Filing date
Publication date
Priority claimed from JP2023515503A external-priority patent/JP7365654B2/ja
Application filed filed Critical
Publication of JP2023182689A publication Critical patent/JP2023182689A/ja
Publication of JP2023182689A5 publication Critical patent/JP2023182689A5/ja
Application granted granted Critical
Publication of JP7822576B2 publication Critical patent/JP7822576B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023169033A 2021-04-22 2023-09-29 抗cldn4-抗cd137二重特異性抗体 Active JP7822576B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2021072429 2021-04-22
JP2021072429 2021-04-22
JP2023515503A JP7365654B2 (ja) 2021-04-22 2022-04-21 抗cldn4-抗cd137二重特異性抗体
PCT/JP2022/018350 WO2022224997A1 (ja) 2021-04-22 2022-04-21 抗cldn4-抗cd137二重特異性抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023515503A Division JP7365654B2 (ja) 2021-04-22 2022-04-21 抗cldn4-抗cd137二重特異性抗体

Publications (3)

Publication Number Publication Date
JP2023182689A JP2023182689A (ja) 2023-12-26
JP2023182689A5 true JP2023182689A5 (cg-RX-API-DMAC7.html) 2025-04-28
JP7822576B2 JP7822576B2 (ja) 2026-03-03

Family

ID=83722348

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023515503A Active JP7365654B2 (ja) 2021-04-22 2022-04-21 抗cldn4-抗cd137二重特異性抗体
JP2023169033A Active JP7822576B2 (ja) 2021-04-22 2023-09-29 抗cldn4-抗cd137二重特異性抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023515503A Active JP7365654B2 (ja) 2021-04-22 2022-04-21 抗cldn4-抗cd137二重特異性抗体

Country Status (21)

Country Link
US (2) US12227586B2 (cg-RX-API-DMAC7.html)
EP (1) EP4327823A4 (cg-RX-API-DMAC7.html)
JP (2) JP7365654B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230171465A (cg-RX-API-DMAC7.html)
CN (1) CN117222672A (cg-RX-API-DMAC7.html)
AR (1) AR125398A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022262542A1 (cg-RX-API-DMAC7.html)
CA (1) CA3217637A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003100A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015630A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230490A (cg-RX-API-DMAC7.html)
DO (2) DOP2023000230A (cg-RX-API-DMAC7.html)
EC (1) ECSP23087918A (cg-RX-API-DMAC7.html)
IL (1) IL307744A (cg-RX-API-DMAC7.html)
JO (1) JOP20230261A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012432A (cg-RX-API-DMAC7.html)
PE (1) PE20241357A1 (cg-RX-API-DMAC7.html)
SA (1) SA523451235B1 (cg-RX-API-DMAC7.html)
TW (1) TW202309083A (cg-RX-API-DMAC7.html)
WO (1) WO2022224997A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202310292B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4524248A4 (en) * 2022-05-12 2026-07-01 Astellas Pharma Inc MULTISPECIFIC ANTI-TAA AND ANTI-CD3 ANTIBODY
CN119997975A (zh) * 2022-10-19 2025-05-13 安斯泰来制药株式会社 抗cldn4-抗cd137双特异性抗体通过与pd-1信号抑制剂的组合在癌症治疗中的应用
EP4786497A1 (en) 2023-09-25 2026-08-05 Astellas Pharma Inc. Anti-mertk agonist antibody, anti-mertk bispecific antibody, and use thereof
WO2026042803A1 (ja) * 2024-08-21 2026-02-26 アステラス製薬株式会社 がん治療におけるプラチナ系薬剤との組み合わせによる抗cldn4-抗cd137二重特異性抗体の使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
KR100999844B1 (ko) 2006-07-19 2010-12-13 네오벌브 테크놀러지스 인크 고효율 방열 모듈을 구비한 고출력 led 조명장치
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
PL2346994T3 (pl) 2008-09-30 2022-04-19 Ablexis, Llc Myszy knock-in do wytwarzania chimerycznych przeciwciał
JP2014193853A (ja) 2013-03-01 2014-10-09 Japan Health Sciences Foundation 抗体、フラグメント、医薬組成物、分子及び腫瘍マーカー
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
JP2021510064A (ja) 2018-01-05 2021-04-15 中外製薬株式会社 細胞傷害誘導治療剤
WO2019178356A1 (en) 2018-03-14 2019-09-19 Dana-Farber Cancer Institute, Inc. Engineered cells, t cell immune modulating antibodies and methods for using the same
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40

Similar Documents

Publication Publication Date Title
JP2024109678A5 (cg-RX-API-DMAC7.html)
JP2023509448A5 (cg-RX-API-DMAC7.html)
JP2022079549A5 (cg-RX-API-DMAC7.html)
JP2022548783A5 (cg-RX-API-DMAC7.html)
JP2021521843A5 (cg-RX-API-DMAC7.html)
RU2019118359A (ru) Антитело к cd73 человека
JP2024542194A5 (cg-RX-API-DMAC7.html)
JP2023540526A5 (cg-RX-API-DMAC7.html)
JP2024056817A5 (cg-RX-API-DMAC7.html)
JP2019054802A5 (cg-RX-API-DMAC7.html)
JP2023543031A5 (cg-RX-API-DMAC7.html)
JP2024541680A5 (cg-RX-API-DMAC7.html)
JP2020525032A5 (cg-RX-API-DMAC7.html)
JP2018527919A5 (cg-RX-API-DMAC7.html)
JP2018521638A5 (cg-RX-API-DMAC7.html)
JP2018535650A5 (cg-RX-API-DMAC7.html)
JP2025032102A5 (cg-RX-API-DMAC7.html)
JP2022540083A5 (cg-RX-API-DMAC7.html)
JP2023509373A5 (cg-RX-API-DMAC7.html)
JP2023516195A5 (cg-RX-API-DMAC7.html)
JP2020515277A5 (cg-RX-API-DMAC7.html)
JP2025501775A5 (cg-RX-API-DMAC7.html)
JP2023508674A5 (cg-RX-API-DMAC7.html)
JP2023543493A5 (cg-RX-API-DMAC7.html)
JP2016518333A5 (cg-RX-API-DMAC7.html)